In vivo Evaluation of Lymph Nodes Using Quantitative Ultrasound

项目摘要 这项申请提出了一项由威尔·康奈尔医学(WCM)在新的 纽约州约克市，作为与GE Research(GER)在纽约州尼斯卡尤纳和斯通市合作的牵头组织 布鲁克医学(SBM)附属于纽约州立大学石溪分校。建议数 该项目解决了对可靠、高度敏感的检测淋巴结转移的手段的需求 并与原发淋巴瘤和良性病变的淋巴结节相鉴别。这 这一能力将有助于改进疾病的分期和治疗。因此，我们试图验证现有的 WCM和SBM使用定量超声(QUS)在先前的研究中获得了令人鼓舞的结果 通过应用和评估这些有前景的方法来检测淋巴结转移的方法 改装临床扫描仪获取内科患者的超声回波信号数据 可疑淋巴结的超声引导细针活检(FNAs)。该研究将包括一项 疾病类型的范围比以往任何时候都要大得多，患者群体也更加多样化 在迄今为止的研究中是可能的。验证工作将为QUS开发、部署和验证应用程序- 基于在临床扫描仪中实现的对LNS的检测和表征。成功的验证将 为将基于QUS的LN评估方法应用于临床超声检查奠定基础 扫描仪。这类仪器将能够在手术室中评估可疑的淋巴结 或在手术前在检查室内。合作的研究人员将在 以下是一般方式：WCM将提供项目监督和协调，并将应用、改进和测试 QUS和分类方法；GER将提供超声仪器，并将开发和 验证扫描仪的QUS应用程序；SBM将招募患者并获得超声波和 接受淋巴结FNAs检查的患者的细胞病理学资料。

Project Summary This application proposes a collaborative study to be performed by Weill Cornell Medicine (WCM) in New York, NY, as the lead organization in collaboration with GE Research (GER) in Niskayuna, NY, and Stony Brook Medicine (SBM) affiliated with the State University of New York in Stony Brook, NY. The proposed project addresses the need for reliable, highly sensitive means of detecting metastases to lymph nodes (LNs) and distinguishing them from primary lymphomas and LNs affected by benign conditions. This capability will allow improved staging and treatment of disease. Accordingly, we seek to validate existing encouraging results obtained in prior studies by WCM and SBM using quantitative-ultrasound (QUS) methods to detect metastases in LNs by applying and evaluating these promising methods using a modified clinical scanner to acquire ultrasonic echo-signal data from patients undergoing medically required ultrasonically guided fine-needle aspirations (FNAs) of suspicious LNs. The study will include a far broader range of disease types from a larger and more-diverse patient population than has been possible in studies to date. Validation efforts will develop, deploy, and validate an application for QUS- based detection and characterization of LNs implemented in a clinical scanner. Successful validation will establish a foundation for incorporation of QUS-based methods for LN evaluation into clinical ultrasonic scanners. Such instruments will be able to evaluate suspicious LNs intra-operatively in the operating room or pre-operatively in the examination room. The collaborating researchers will synergize capabilities in the following general ways: WCM will provide project oversight and coordination and will apply, refine, and test QUS and classification methods; GER will provide ultrasound instrumentation and will develop and validate the QUS application for the scanner; SBM will recruit patients and acquire ultrasonic and cytopathological data from patients undergoing FNAs of their LNs.